AGTR1 and cancer: Despite substantial preclinical evidence implicating AT1R signalling in cancer progression and varied (but often positive) outcomes from meta-analyses of clinical observational studies and retrospective cohort studies, trials specifically designed to evaluate ARBs in oncology remain limited.